Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure: KINGFISHER Study Post Hoc Analysis.

چکیده

To evaluate visual and anatomical outcomes of brolucizumab 6 mg versus aflibercept 2 mg in subgroups of participants with/without prior anti-VEGF treatment for diabetic macular edema in the KINGFISHER study. Post hoc analysis of the KINGFISHER study. Of 517 participants randomized, 370 (71.6%) were…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط